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ABSTRACT 
What is new? Many methods exist to help explain the impact of research 
but little work has been undertaken to centrally involve the 
patient point of view. This paper discuss the need for 
patient involvement in impact assessment and a call for 
action going forward. 
What was the 
approach? 
The International School of Research Impact Assessment 





structure for evaluation and stressing the importance of 
context and stakeholder engagement (Adam et al, 2018). 
Based on the principles outlined in the paper the authors 
considered possible structures to include patients within 
research impact assessment. 
What is the scholarly 
impact? 
Facilitated consultation and targeted patient-reported 
impact measures would give research evaluators a better 
understanding of impact from the patient perspective. For 
health and social care research the patient perspective is a 
key lens in ensuring relevance and accountability. 
What is the wider 
impact? 
Greater patient involvement and engagement with the 
impact assessment process may require adaptations to 
current cultural norms. It is accepted that impact is 
measured over time. Patient involvement in impact 
assessment needs to be facilitated with a similar mindset 
with the necessary underlying resource. 
Keywords Patient involvement, impact juries, PROMs 
SYNOPSIS 
All research funders wish to see meaningful impact of the work they fund. Methodologies 
have been produced over several years that help explain the impact of research over a 
broad range of professions (Greenhalgh et al, 2016). The most widely used technique to 
measure impact is the Payback Model (Buxton and Hanney, 1996), and the best-known 
approach within the UK is the Research Excellence Framework (REF), an exercise that 
judges universities across disciplines and which some other countries are looking to 
emulate (Morgan, 2014). 
For health and related research impact in particular, we believe we need to be more 
guided by the patients for whom the research was undertaken. Patients have been 
involved in research prioritisation and peer review, and some health research funders 
look to coproduce their work with patients and patient groups (Kaye et al, 2012). It seems 
odd therefore that work defining the impact of research has not had the same level of 
patient input. We believe facilitated consultation and targeted patient-reported impact 
measures would give research evaluators a better understanding of impact from the 
patient perspective. 
BACKGROUND 
In this essay, we discuss the importance of incorporating the patient viewpoint into 





two possible models for activities to engage the public in an ongoing dialogue in this 
contemporary and, at times, contested area. 
Impact assessment itself is a process that can be undertaken during a research program 
or body of work’s lifetime (formative) or undertaken after a body of work, research or 
funding has completed (summative). Funders will have their own particular impact ‘lens’ 
which will drive how they see impact and the methodologies they will use during any 
evaluation. Some funders will wish to take a retrospective approach and look back at how 
research may have had an effect in terms of a greater accountability. Some will look to 
learn lessons for purposes of advocacy or to ensure better allocation of funding in future 
rounds. 
No matter what the impact lens, how to define the impact of research has been the focus 
of major debate between those responsible for allocating public funds to research, and 
the wider researcher community. For instance the forthcoming Research Excellence 
Framework (REF) 2021 assessment exercise has defined impact as ‘any effect on, change 
or benefit to the economy, society, culture, public policy or services, health, the 
environment or quality of life, beyond academia’ (UKRI, 2018). Although the definition 
mentions ‘effects’, the danger still remains that researchers describe impact in terms of 
activities more relevant to them, than the changes these activities are intended to bring 
about to the public. That is unsurprising as impact may take place years after the research, 
and at some distance from the institution(s) that undertook the research originally. If 
research on medical interventions takes 17 years (on average) to get into practice or to 
be adopted (Morris et al., 2011) it is understandable that the academic and funder 
community defaults to measurements that are common within a field. 
To break this unconscious or institutional bias, a better question than ‘how’ we define the 
impact of research might be ‘who gets to define impact?’ The meaning and measurement 
of impact seems to be a closed-shop debate between those who fund and those who do 
research. There is work about evaluating the impact of research to justify it (rightly) to 
the donors or taxpayers that provide the money, but with less regard to perhaps the key 
stakeholder in health research: the patient. When funding bodies, such as the National 
Institute for Health Research (NIHR), link health research investment to both wealth 
creation (NIHR, 2018) and population outcomes it is possible that wealth creation 
becomes the default primary outcome as it is more straightforward to measure and easier 
to understand. Wealth creation, although important to justify investment in research, is 
unlikely to be many patients’ primary goal. 
It is assumed that a principle of any healthcare system is to put patients at the heart of 
everything it does. Over the past few years much excellent work has gone into involving 
patients with research. Within the UK groups such as INVOLVE and the James Lind 
Alliance have worked with researchers to engage with patients and patient groups over 





allocation and outcome review can all involve patients, but this needs to be more than 
just involvement in specific parts of the research pipeline. We argue that patients should 
be involved at a more systemic level in defining what impact means to them and how to 
assess such impact. 
PATIENTS, PUBLIC AND RESEARCH IMPACT EVALUATION 
There is a danger that whilst researchers and funders get together to work on a set of 
measurements and methodologies to identify and explain impact to each other, patients 
are being left out. We hope that research overall will lead to improvements for patients 
and the running of healthcare systems and we know that implementation of innovation 
into the NHS is not easy. A recent publication from the Health Foundation (Horton et al., 
2018) stated ‘the success of a complex intervention is likely to depend heavily on its 
context: the underlying systems, culture and circumstances of the environment in which 
it is implemented.’ Excellence in research is not enough, the context in terms of the health 
care system is key. As such how do we really measure the impact of research in terms of 
patient and public benefit, in a manner that is understandable by and acceptable to the 
patient cohorts themselves, a key part of that context? 
The impact of health research is often described in a language of outputs and outcome 
(Morgan Jones et al, 2016), that may resonate with the patient cohort involved in the 
study itself, or those involved in health research more generally. Patients may be asked 
to judge the research itself or to comment on the results. However, do we engage with 
patients enough when undertaking research evaluations? Are we using them as data 
points rather than co-producing assessments? 
Without including the patient voice in research impact assessment there is a danger we 
end up with evaluations that miss the broader context.  An analogy can be seen within 
the world of health technology assessment (HTA). Within the UK, NICE undertakes 
detailed and respected reviews but very much from the view of cost-effectiveness of the 
healthcare system itself. However, there is a broader context which is not taken fully into 
account (if at all). In their review exploring how cost benefit analyses have moved away 
from a societal perspective to a more budget-based, ‘payer’ perspective, Johannesson 
and colleagues indicate not just how much chronic conditions cost wider society, but 
more importantly cost the patients themselves (Johannesson et al, 2009). 
This essay is not here to argue whether such broader costs should be more fully 
recognised in clinical and cost effectiveness analyses by government bodies around the 
world. However, it would be a shame to replicate such an omission in the impact 
assessment of the research that is funded on our behalf. How can we ensure this does 
not happen? The most influential impact assessment frameworks within the UK ‘flag’ 
certain expectations and wants. The REF template implies that impact will be achieved by 





and fundee (although we note Research England’s recent consultation on REF2021 (UKRI, 
2019) has indicated a greater interest in measuring public engagement and the use of lay 
members in the assessment panel structure). 
A WAY FORWARD 
The authors believe the lack of meaningful work to include patients in the co-production 
of research assessment limits our ability to understand how research may or may not 
affect health and social care pathways. Without patient co-production of impact 
assessment, the ‘closed loop’ conversation will continue. This may be more problematic 
than people believe. In a recent paper reviewing models of research policy relations 
between government and the University sector, Boswell and Smith (2017) make it clear 
there are a number of potential disconnects between parties. As such, ‘assessments 
aiming to trace the impact of research on particular policy outcomes are likely to miss a 
potentially broader, more diffuse kind of conceptual influence’. 
The time is right to ask for more consideration of the patient viewpoint. The International 
School of Research Impact Assessment (ISRIA) recently issued a statement suggesting a 
basic structure for evaluation and stressing the importance of context and stakeholder 
engagement (Adam et al, 2018). Now is the time to understand and include the patient, 
to engage and co-produce. 
At the recent 25th Cochrane Colloquium two of the authors discussed and asked for views 
on two linked approaches in which patient-defining impact assessment may be possible. 
The first (Citizen´s Juries) would encourage and help patients define what they hoped 
research might achieve at the outset (at a ‘macro’, i.e. programme or funder, level) and 
create a set of patient-led indicators. The indicators could be used to monitor whether 
research, if adopted and implemented, had a noticeable effect on the patient cohort it 
was funded to help. The second model (Patient-Reported Impact Measures) would be 
based post-research at a ‘meso’ or ‘micro’ level to create a meaningful set of measures 
on the patient or public experience of defined changes within a known health or social 
care pathway. The second model may be influenced or defined by the patient-led 
indicators discussed previously. 
CITIZENS’ JURIES 
Research benefits people in long-term, indirect and unpredictable ways (Guthrie et al, 
2018), and we need to find ways of identifying impact which allow blue skies, curiosity-
driven research to continue to flourish. A narrow focus on the short term or metric base 
may produce a shrivelled and pedestrian body of knowledge.  For patients to be 
meaningfully involved in assessing the impact of research they may need to consider a 
number of contexts. Early stage or blue-sky research is needed and beneficial but is not 





patients and the public define impact indicators that are predictive by nature. We would 
need to use techniques that help gain input from the appropriate microcosm of the 
correct population cohort that ultimately any early stage research would be addressing. 
The use of our first proposed model, Citizens’ Juries, may be applicable here. A recent 
review by Jackie Street and colleagues discussed their use within health policy 
formulation (Street at al, 2014), and the Northern Health Science Alliance (NHSA) used 
this model to ensure that its Connected Health Cities program would be an acceptable 
vehicle for patient data (Connected Health Cities 2017). More recently, the Irish 
Government received recommendations on abortion from such a jury (Wise 2017). 
Citizens’ Juries may make an excellent forum to analyse whole programmes or funding 
streams from the patient perspective. Our discussion at the Cochrane mirrored some of 
the issues raised by Irvin and Stansbury in 2014, including cost and the time commitment 
needed by participants. However, it is interesting to note that Juries have been run online 
(albeit outside the healthcare arena) (Romanach et al, 2013). It is also important to ensure 
appropriate representation to avoid any jury being ‘heavily influenced by special interest 
groups’ as Irvin described. An interesting suggestion was that crowdsourcing could be 
used to help identify participants and we will be investigating all online techniques over 
the coming months. 
Our colleagues at the Colloquium made a comparison between the proposed use of 
Citizens’ Jurys to that of the general legal system. How do we identify appropriate ‘judges’ 
and what is the underpinning ‘legal system’ (the impact laws/frameworks/precedents) 
that they will interpret for the jurors? Legal systems have established themselves over 
time whereas the ‘impact system’ is nascent. We would need to ensure that our use of 
frameworks was curated transparently, with results reported openly and accessibly, to 
establish precedents over time. 
PATIENT-REPORTED IMPACT MEASURES 
There are methodologies and tools used in HTA that could help identify or explain the 
impact of research from a patient viewpoint. Patient-reported outcome measures 
(PROMs) are commonly used within clinical trials as a tool to measure the cost 
effectiveness of a treatment from the patient perspective. They are also used in 
institutional settings where assessment considerations are addressed across a broader 
‘ecosystem’. 
PROMs are designed on the basis of close discussion with patients about their own 
concerns for particular conditions and are increasingly being used in routine clinical 
practice to check if treatment improves aspects of health, mobility and socialisation. 





tools for designing clinical care to suit the needs and priorities of individual patients’. Can 
we use PROMs to produce a more collective Patient-Reported Impact Measure (PRIM)? 
Such techniques have been extended to evaluate patients’ experiences and assessment 
of the quality of care they have received (patient-reported experience measures, PREMs) 
(Male et al, 2017). Recently, work has been undertaken to combine patient-reported 
outcomes with clinical performance measures to produce patient-reported outcome 
performance measures (PRO-PM) (Basch et al, 2014). The authors believe it should be 
possible to collect data that allows the construction of a condition- or pathway-specific 
PRIM. This would allow the ability to broadly measure the actual impact of research on a 
patient cohort, perhaps building on what a Citizens’ Jury believed the impact might be. 
There are some concerns. We do need to try and develop a level of objectivity, and to 
quote a colloquium participant we need to ‘Ask patients what they care about and try to 
measure that, not what fits your idea’ (Francis Ak’enamé, Twitter 2018). For PRIMs to be 
and remain meaningful we need agility to test models with patients and adapt within the 
system as we go and not to predetermine the model and outcome. The Jury model 
therefore interlinks with PRIMs. Strategically, a feedback loop is necessary. 
SUMMARY 
To be clear, this is not research prioritisation or patients on another committee but a 
patient- and practitioner-led exploration of impact, explicitly setting out to include the 
patient voice. What should not have to be debated is the need to include patients in 
considerations of what impact means, or processes around its assessment – not just as 
passengers, but as pilots. Otherwise, who are we doing this research for? 
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